Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
LYRA THERAPEUTICS INC
LYRA | US
1.29
USD0.03
2.38%
LYRA | US
About LYRA THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
05/03/2026
Close
1.29
Open
1.27
High
1.32
Low
1.22
Lyra Therapeutics Inc. a clinical-stage biotechnology company focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear nose and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210 an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS) which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical Inc. and changed its name to Lyra Therapeutics Inc. in July 2018. Lyra Therapeutics Inc. was incorporated in 2005 and is headquartered in Watertown Massachusetts.
View LessLYRA | US
Risk
125.0
Sharpe
-0.27
Luna's Score
43/100
Recommendation
Sell
Luna says (LYRA | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
What's not Working
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Debt to Equity (> 0.75)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
150.8%1 month
125.0%3 months
147.6%6 months
118.8%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.49
Debt to equity
1.19
Debt to assets
0.39
Ent. to EBITDA
0.66
Ent. to rev.
153.77
PEG
-
Other Fundamentals
EBITDA
-74.33M
MarketCap
84.44M
MarketCap(USD)
84.44M
Div. yield
-
Op. margin
-2.98K
Erngs. growth
-
Rev. growth
30.60
Ret. on equity
-156.52
Short ratio
4.28
Short perc.
5.44
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.61
Range1M
1.14
Range3M
3.68
Volumes: Market Activity
Rel. volume
0.30
Price X volume
26.35K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.66 | 0.53 | Expensive |
| Ent. to Revenue | 153.77 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.49 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 147.59 | 72.80 | Riskier |
| Debt to Equity | 1.19 | -1.23 | Expensive |
| Debt to Assets | 0.39 | 0.25 | Expensive |
| Market Cap | 84.44M | 3.66B | Emerging |
